Drug updated on 9/4/2024
Dosage Form | Injection (intravenous; 345 mg/2.3 mL (150 mg/mL), 1,200 mg/8 mL (150 mg/mL)) |
Drug Class | Angiopoietin-like 3 inhibitors |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 5 years and older, with homozygous familial hypercholesterolemia.
Latest News
Summary
- Evkeeza (evinacumab-dgnb) is indicated as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients aged 5 years and older with homozygous familial hypercholesterolemia.
- This summary is based on the review of two systematic review(s)/meta-analysis(es). [1-2]
- LDL-C Reduction: Evinacumab led to a significant reduction in LDL-C levels, with a mean difference of -33.123% (95% CI, -48.639% to -17.606%, P < 0.0001) compared to placebo.
- Triglycerides Reduction: Evinacumab significantly decreased triglyceride levels by -50.959% (95% CI, -56.555% to -45.362%, P < 0.0001).
- HDL-C Reduction: Evinacumab also resulted in a reduction of HDL-C levels, with a mean difference of -12.773% (95% CI, -16.359% to -9.186%, P < 0.0001).
- The incidence of at least one treatment-emergent adverse event was not significantly different between the evinacumab and placebo groups (relative risk 1.080, 95% CI, 0.901-1.296, P = 0.405).
- No significant safety concerns or specific adverse effects were highlighted for any particular population or subgroup, including those with familial hypercholesterolemia (FH).
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Evkeeza (evinacumab-dgnb) Prescribing Information. | 2023 | Regeneron Pharmaceuticals, Inc., Tarrytown, NY |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
The promising novel therapies for familial hypercholesterolemia. | 2022 | Journal of Clinical Laboratory Analysis |
Efficacy and safety of evinacumab for the treatment of hypercholesterolemia: a meta-analysis. | 2021 | Journal of Cardiovascular Pharmacology |